Navigation Links
Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
Date:10/31/2007

WESTMINSTER, Colo., Oct. 31 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that Paul L. Berns, President and CEO, will present a corporate overview at the 2007 Acumen BioFin Rodman & Renshaw Conference in New York.

The Company's presentation will take place at 8:50 a.m. (Eastern) on Tuesday, November 6, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through November 20, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for which the Company expects to initiate a Phase 1 trial in patients with advanced solid tumors in the fourth quarter of 2007. For additional information, please visit the Company's website at http://www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
4. Researchers Present Ways To Reduce The Risk Of Dementia
5. Researchers Present Data Regarding The Efficiency Of Herbs
6. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
7. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
8. Drug Reactions First Present Themselves In The Mouth
9. Reminiscing Into The Past Makes You Dissatisfied With The Present
10. Living In The Past Indicates Dissatisfaction With Present
11. Movies Represent Coma In A Wrong Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, a ... charity drive to generate community support for efforts to educate the local population on ... for all types of cancer. , Each day in America, roughly 4,600 new ...
(Date:8/18/2017)... ... 2017 , ... MLM Insurance Group, a Miami area provider ... is working to support the Take Stock In Children Foundation during a regional ... The Take Stock In Children Foundation (TSC) offers guidance and assistance to low ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Emotions are sacred, valid, honored, encouraged. ... Louis-based positive education company Generation Mindful. To help change the mindset of parents and ... emotional skills, she created the Time-In Toolkit, which launched on Kickstarter 3 weeks ago ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Inc. magazine ... list, the most prestigious ranking of the nation's fastest-growing private companies. This marks the ... exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Three Narrow ... Roads” is the creation of published author, Rev. Dr. Burnett King Sr., is currently ... coach and founder of the Faith Track Club, Inc., a track-and-field program geared towards ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/2/2017)... a next-generation full-service pharmacy, has announced the launch of its ... Washington D.C. metropolitan area. CaryRx aims to ... through the convenience of its patient-friendly mobile app. Prescriptions can ... to any location in D.C. ... Washington D.C. ," says Areo Nazari , ...
Breaking Medicine Technology: